Drugs causing prostate-specific antigen changes: the food and drug administration adverse event reporting system combined with Mendelian randomization analysis
- 18 September 2024
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 23 (12) , 1515-1522
Abstract
BackgroundProstate cancer is one of the most common malignancies in men worldwide, and prostate-specific antigen (PSA) screening is widely used for its early detection. Drug use may affect PSA levels, but the effect for most drugs is currently unknown.MethodsThis study first investigated drugs related to PSA changes through the Food and Drug Administration Adverse Event Reporting System (FAERs) database, and then used a Mendelian randomization (MR) method to explore the causal relationship between specific drugs and PSA changes using a genome-wide association study (GWAS) data. The statistical analysis software SAS and R were used in the study.ResultsThrough analysis of the FAERs database, 22 drugs were found to be associated with an increase in PSA, and 14 drugs were associated with a decrease in PSA. MR analysis showed that the use of tamsulosin may lead to an increase in PSA. Heterogeneity test, horizontal pleiotropy test and leave-one-out Analysis verified the stability of the results. MR analyses for other drugs did not show statistical significance.ConclusionThis study provided a basis for better understanding the impact of medications on prostate health, helping to avoid overdiagnosis or underdiagnosis of high-risk patients. However, research still requires larger-scale validation and in-depth exploration.Keywords
Funding Information
- Scientific Activities of Selected Returned Overseas Professionals (20210005)
- Shanxi Provincial Basic Applied Research Project (20210302124611)
- Shanxi Scholarship Council of China (2021-164)
- Shanxi Province Basic Research Program (202303021221211)
This publication has 16 references indexed in Scilit:
- Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamideUrologic Oncology: Seminars and Original Investigations, 2023
- Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) databaseInternational Immunopharmacology, 2021
- Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: Results from a randomized pilot studyInternational Journal of Urology, 2018
- Reading Mendelian randomisation studies: a guide, glossary, and checklist for cliniciansBMJ, 2018
- Comparison of α-Blocker Monotherapy and α-Blocker plus 5α-Reductase Inhibitor Combination Therapy Based on Prostate Volume for Treatment of Benign Prostatic HyperplasiaJournal of International Medical Research, 2012
- Estimates of cancer incidence and mortality in Europe in 2008European Journal of Cancer, 2010
- α‐blockers improve chronic ischaemia of the lower urinary tract in patients with lower urinary tract symptomsBJU International, 2007
- EAU Guidelines on Prostate CancerEuropean Urology, 2005
- PSA Doubling Time as a Predictor of Clinical Progression After Biochemical Failure Following Radical Prostatectomy for Prostate CancerMayo Clinic Proceedings, 2001
- Prostate-specific antigenSeminars in Cancer Biology, 1999